A rare adverse reaction of sorafenib

Sorafenib is a multikinase inhibitor thought to target vascular endothelial growth factor and its receptor. The European Medicines Agency (EAMA) and Food and Drug Administration (FDA) approved the use of sorafenib in late-stage hepatic cellular cancer (HCC) on October 30, 2007, and November 19, 2007, respectively. It is the only drug approved for use in the systematic treatment of primary HCC, and it offers renewed hope for middle- and late-stage liver cancer patients. Conventional use of sorafenib is 400 mg orally, twice daily, until tumor progression or patient death. The following is a report of a serious episode of skin rash in a liver cancer patient at our hospital subsequent to treatment with sorafenib.